<PAGE>
<TABLE>
<CAPTION>
-------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION -----------------------------
FORM 4 WASHINGTON, D.C. 20549 OMB APPROVAL
-------- -----------------------------
/ / CHECK THIS BOX IF NO STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OMB NUMBER: 3235-0287
LONGER SUBJECT TO EXPIRES: SEPTEMBER 30, 1998
SECTION 16. FORM 4 OR Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, ESTIMATED AVERAGE BURDEN
FORM 5 OBLIGATIONS MAY Section 17(a) of the Public Utility Holding Company Act of 1935 or HOURS PER RESPONSE .... 0.5
CONTINUE. SEE Section 30(f) of the Investment Company Act of 1940 -----------------------------
INSTRUCTION 1(b).
(Print or Type Responses)
------------------------------------------------------------------------------------------------------------------------------------
<S><C>
1. Name and Address of Reporting Person* 2. Issuer Name AND Ticker or Trading Symbol 6. Relationship of Reporting Person(s)
to Issuer (Check all applicable)
X Director 10% Owner
Buffington William I. ROSETTA INPHARMATICS, INC. (RSTA) ---- ----
--------------------------------------------------------------------------------------------- Officer (give Other
(Last) (First) (Middle) 3. IRS or Social Security 4. Statement for ---- title ---- (specify
Number of Reporting Month/Year below) below
Person (Voluntary) -------------------------------------
395 PAGE MILL ROAD, M/S A3-18 August 2000
-------------------------------------------- --------------------- 7. Individual or Joint/Group Filing
(Street) 5. If Amendment, (Check Applicable Line)
Date of Original X Form filed by One Reporting Person
(Month/Year) ---
Form filed by More than One
PALO ALTO, CA 94306 09/11/00 --- Reporting Person
------------------------------------------------------------------------------------------------------------------------------------
(City) (State) (Zip) TABLE I - NON-DERIVATIVE SECURITIES ACQUIRED, DISPOSED OF, OR BENEFICIALLY OWNED
------------------------------------------------------------------------------------------------------------------------------------
1. Title of Security 2. Trans- 3. Trans- 4. Securities Acquired (A) 5. Amount of 6. Owner- 7. Nature
(Instr. 3) action action or Disposed of (D) Securities ship of In-
Date Code (Instr. 3, 4 and 5) Beneficially Form: direct
(Instr. 8) Owned at Direct Bene-
(Month/ End of (D) or ficial
Day/ ------------------------------------------- Month Indirect Owner-
Year) (A) or (I) ship
Code V Amount (D) Price (Instr. 3 (Instr. 4) (Instr. 4)
and 4)
------------------------------------------------------------------------------------------------------------------------------------
COMMON STOCK 8/08/00 C 2,285,714 A 2,285,714 I Held by Agilent
Technologies,
Inc. (2)
------------------------------------------------------------------------------------------------------------------------------------
COMMON STOCK 8/08/00 C 459,792 A 459,792 I Held by Agilent
Technologies,
Inc. (2)
------------------------------------------------------------------------------------------------------------------------------------
COMMON STOCK 8/08/00 X 714,285 A $14.00 714,285 (1) I Held by Agilent
Technologies,
Inc. (2)
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. (Over)
* If the form is filed by more than one reporting person, SEE Instruction 4(b)(v). SEC 1474 (7-97)
POTENTIAL PERSONS WHO ARE TO RESPOND TO THE COLLECTION OF INFORMATION
CONTAINED IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM
DISPLAYS A CURRENTLY VALID OMB CONTROL NUMBER.
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
FORM 4 (CONTINUED) TABLE II - DERIVATIVE SECURITIES ACQUIRED, DISPOSED OF, OR BENEFICIALLY OWNED
(E.G., PUTS, CALLS, WARRANTS, OPTIONS, CONVERTIBLE SECURITIES)
------------------------------------------------------------------------------------------------------------------------
1. Title of Derivative Security 2. Conver- 3. Trans- 4. Transac- 5. Number of Deriv- 6. Date Exer-
(Instr. 3) sion or action tion Code ative Securities Ac- cisable and Ex-
Exercise Date (Instr. 8) quired (A) or Dis- piration Date
Price of (Month/ posed of (D) (Month/Day/
Deriv- Day/ (Instr. 3, 4, and 5) Year)
ative Year)
Security
--------------------
Date Expira-
-------------------------------------- Exer- tion
cisable Date
Code V (A) (D)
<S><C>
------------------------------------------------------------------------------------------------------------------------
SERIES D PREFERRED STOCK 1:1 08/08/00 C 2,285,714 Immed
------------------------------------------------------------------------------------------------------------------------
SERIES E PREFERRED STOCK 1:1 08/08/00 C 459,792 Immed
------------------------------------------------------------------------------------------------------------------------
Put Options (obligation to buy) $14.00 08/08/00 X 714,285 08/08/00 08/08/00
------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------
<CAPTION>
------------------------------------------------------------------------------------------
7. Title and Amount of Under- 8. Price 9. Number 10. Owner- 11. Nature
lying Securities of of Deriv- ship of In-
(Instr. 3 and 4) Deriv- ative Form direct
ative Securi- of De- Bene-
Secur- ties rivative ficial
ity Bene- Secu- Own-
(Instr. ficially rity: ership
5) Owned Direct (Instr. 4)
at End (D) or
Amount or of Indi-
Title Number of Month rect (I)
Shares (Instr. 4) (Instr. 4)
<S><C>
------------------------------------------------------------------------------------------
Common Stock 2,285,714 0 I Held by Agilent
Technologies,
Inc. (2)
------------------------------------------------------------------------------------------
Common Stock 459,792 0 I Held by Agilent
Technologies,
Inc. (2)
------------------------------------------------------------------------------------------
Common Stock 714,285 (1) 0 I Held by Agilent
Technologies,
Inc. (2)
------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------
Explanation of Responses:
(1) On August 8, 2000, pursuant to a put right exercised by the issuer, Agilent Technologies, Inc. purchased
714,285 shares of the issuer's common stock at $14.00 per share, the actual initial public offering price.
(2) Mr. Buffington is the General Manager of Bioscience of Agilent Technologies, Inc. Mr. Buffington disclaims
beneficial ownership of shares held by Agilent Technologies, Inc. except to the extent of his pecuniary
interest therein.
/s/ John W. Robertson 9/21/2000
----------------------------------- -----------
**Intentional misstatements or omissions of facts constitute Attorney In Fact for Date
Federal Criminal Violations. SEE 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). William I. Buffington
Note: File three copies of this Form, one of which must be manually signed.
If space is insufficient, SEE Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained
in this form are not required to respond unless the form displays a currently
valid OMB Number.
Page 2
SEC 1474 (7-97)
</TABLE>
<PAGE>
POWER OF ATTORNEY
The undersigned hereby constitutes and appoints Stephen H. Friend, John
J. King, II, Gregory Sessler, and John W. Robertson, and each of them, his
or her true and lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer, director, and/or person who holds more
than 10% of the stock of Rosetta Inpharmatics, Inc. (the "COMPANY"), Forms 3,
Forms 4 and Forms 5 in accordance with Section 16(a) of the Securities
Exchange Act of 1934, as amended (the "EXCHANGE ACT"), and the rules
thereunder;
(2) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete and execute any
such Forms 3, Forms 4 or Forms 5 and timely file any such forms with the
United States Securities and Exchange Commission and any other authority; and
(3) take any other action of any type whatsoever in connection with
the foregoing which, in the opinion of such attorney-in-fact, may be of
benefit to, in the best interest of, or legally required by, the undersigned,
it being understood that the documents executed by such attorney-in-fact on
behalf of the undersigned, pursuant to this Power of Attorney shall be in
such form and shall contain such terms and conditions as such
attorney-in-fact may approve in his or her discretion.
The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary or proper to be done in the exercise of any of the
rights and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or his or her substitute or substitutes, shall lawfully do
or cause to be done pursuant to this power of attorney. The undersigned
acknowledges that the foregoing attorneys-in-fact, in serving in such
capacity at the request of the undersigned, are not assuming, nor is the
Company assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect from
September 11, 2000 through September 22, 2000 with respect to the
undersigned's holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing
delivered to the attorneys-in-fact.
/s/ William I. Buffington
---------------------------------------
William I. Buffington
